Key statistics dashboard for Genelux Corporation (GNLX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer.
Stock Data
| Price | $2.34 |
| Market Cap | $105M |
| Beta | 0.46 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.78 |
| Price / Book | 6.89 |
| P/S | 13844.48 |
| P/FCF | -3.86 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -1762.50% |
| EBIT Margin | -431725.00% |
| EBITDA Margin | -427375.00% |
| Operating Margin | -445200.00% |
| Net Margin | -422412.50% |
Financial Health
| Current Ratio | 2.39 |
| Quick Ratio | 2.39 |
| Cash Ratio | 1.15 |
| Debt / Equity | 0.15 |
| Debt / Assets | 9.23% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.36 |
| Cash per share | 0.42 |
| FCF per share | -0.64 |
| Tangible Book Value per share | 0.36 |
| Dividend per share | 0.00 |
Related companies: ACIU · ALDX · CADL · CLLS · CTNM · DRTS · LXEO
Explore sector: Healthcare · Biotechnology
More sections of GNLX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks